Pancreatic Ductal Adenocarcinoma. Razvan Popescu Tumor Center Aarau Switzerland
|
|
- Myrtle Welch
- 5 years ago
- Views:
Transcription
1 Pancreatic Ductal Adenocarcinoma Razvan Popescu Tumor Center Aarau Switzerland
2 Teaching aims Discuss role of palliative care in PDAC Metastatic or locally advanced irresectable disease First line Therapies Second line Therapies Novel approaches (Borderline) Resectable disease
3 Epidemiology In Europe fourth most common fatal cancer in men (after lung, colorectal, and prostate) and women (after breast, colorectal and lung) Death due to PC increasing, projected to become second most common fatal cancer by 2030 Life expectancy overall of 5% at 5 years
4 Importance of Supportive and Palliative Care Median Survival of Patients With Pancreatic Cancer Localized/ Resectable months 10% Locally Advanced 6-15 months 30% Metastatic/ Advanced 3-12 months 60%
5 Pancreatic cancer symptom burden Asthenia 85% Weight loss Anorexia Abdominal / epigastric pain Dark urine Jaundice Nausea Back pain Diarrhea Vomiting Steatorrhea Abdominal fullness Thrombophlebitis 2-3%
6 Recent guidelines call for early palliative care as a new standard Potentially Curable Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline 2016: Patients should have full assessment of symptoms, psychological status, and social supports and should receive palliative care early
7 Supportive and Palliative Care Start supportive and palliative care as soon as diagnosis is suspected pancreatic cancer is an EMERGENCY Assess symptoms and their speed of development Consider pain, weight loss, exocrine pancreatic insufficiency, jaundice*, delayed gastric emptying*, VTE, depression, etc. * Biliary obstruction: endoscopic stent placement * Duodenal obstruction: endoscopic metal stent placement
8 Many patients assume they can be cured with palliative measures 1193 patients participating in the Cancer Care Outcomes Research and Surveillance (CanCORS) study receiving chemotherapy for stage IV lung or colorectal cancers 69% lung and 81% colorectal cancer patients did not understand that their treatment was not at all likely to cure their cancer. Inaccurate beliefs were higher among patients who rated their communication with physicians very favorably! Educational level, functional status, and the patient's role in decision making were not associated with such inaccurate beliefs about chemotherapy Weeks JC, et al. Patients' expectations about effects of chemotherapy for advanced cancer. N Engl J Med Oct 25;367(17):
9 Recent Randomized Trials document Impact of EARLY Palliative Care Benefits of OUTPATIENT concurrent palliative care: Avoided admissions and readmissions, increase referral to hospice, Better communication and satisfaction Equal or lowered costs to the health system Equal or better symptom management Equal or improved quality of life Equal or LONGER survival Not a single trial showed harm, added cost, or burden
10 How about systematic early palliative care integration in pancreatic cancer? Many principles can be extrapolated from other trials Metastatic pancreatic cancer patients were randomized between early vs. on-demand palliative care in an Early Palliative Care Italian Study Group (EPCISG) multicenter trial. The early palliative care group had significantly improved QoL, there was no difference in survival Maltoni M et al, Eur J Cancer Sep;65:61-8. doi: /j.ejca
11 Pancreatic cancer symptoms Pain Assess at every visit including response to analgesics May be neuropathic and require co-analgesics RT or Celiac Plexus Block VTE Four- to seven-fold higher in pancreatic cancer than in other common adenocarcinomas, risk highest in first months after diagnosis and increased by chemotherapy Prophylaxis with LMWH reduces VTE but does not improve OS in outpatients- those with previous VT/E - lifelong LMWH Anxiety and Depression 1/3-2/3 of patients Use validated instruments or Are you depressed? Duloxetine or Venlafaxine co-treat neuropathic pain
12 GI problems in Pancreatic Ca Patients Anorexia Early satiety Weight loss Fatigue, weakness Nausea Constipation Ascites Malabsorption Early involvement of nutritionist / dietitian Assess nutritional intake Assess malabsorption Supplement pancreatic enzymes Treat reversible causes like constipation, ascites, delayed gastric emptying /gastroparesis Cachexia
13 GI Problems - Transit Constipation can be due to opioid intake, peritoneal carcinomatosis, ascites, delayed gastric emptying Ascites May be caused by peritoneal carcinomatosis or portal vein thrombosis / obstruction Patients with portal hypertension may respond to diuretics Paracentesis, if repeatedly necessary insert long term catheter Delayed gastric emptying often without obstruction, gastrographin image series may help discriminate If obstruction is not predominant, prokinetics may help NG tube in recurrently vomiting patients,? PEG / PEJ tube
14 Jaundice from biliary tree obstruction Leads to pruritus, risk of cholangitis Best treatment (least invasive) is placement of a stent preferably a metal stent if permanent stent is intended (fewer recurrent obstructions) Plastic stents are cheaper and can be easier removed or exchanged If the tumor is potentially removable, speak to the surgeon as to their preferences re plastic vs. metal stent If endoscopic placement fails percutaneous placement may be an option If cholangitis occurs, emergency antibiotics and stent change may be life saving Surgical bypass is an option
15 Exocrine pancreatic insufficiency Leads to maldigestion, fat malabsorption, and steatorrhea Typically symptoms include abdominal cramping, flatulence, urgency to defecate, weight loss and steatorrhea (greasy, foul-smelling, soft stools that are difficult to flush- may be less prominent if patients limit fat ingestion) Treat patients empirically with adequate doses of oral pancreatic enzyme replacements best ingested with meals IU Lipase Microencapsulated variants better with gastric acid secretion if not efficacious, consider PPI Frequent smaller meals may be preferable
16 Anorexia - Cachexia Weight loss and Anorexia loss of appetite is common and multifactorial, but in many cases reversible Dysgeusia, xerostomia Poor appetite Poor GI transit/ motility or absorption Early satietey (ascites, hepatomegaly) Weight loss > 5% correlates with worse mortality Cachexia is characterized by Excessive loss of lean body (skeletal muscle) mass Cytokine activation and chronic inflammatory response Increased basal metabolic rate / hypermetabolic state Far more than poor caloric intake Correlates with poor prognosis, directly linked to severity
17 Cachexia management Established Cachexia syndrome difficult to manage supportive care, psychological assistance, discouraging relatives to force feed Pre-cachexia more likely to respond to therapy ideally managed by teams including pall care specialists, psychologists and nutritionalists Small meals, supplements Physical exercise Trials of dexamethasone or medroxyprogesteroneacetate (short term, VTE risk!) may be warranted Clinical trial participation warranted
18 Locally advanced inoperable / metastatic Pancreatic Cancer
19 Predicting Prognosis in advanced PDAC The MSKCC Prognostic Score (MPS) A modification of the Glasgow Prognostic Score (CRP >10 and Albumin < 3.5 g/dl) Neutrophil / Lymphocyte Ratio (NLR) >4 and Albumin < 4 g/dl) get each 1 point Andrew Cheung Yang, Abstract 4105, ASCO 2017
20 Advanced inoperable/ metastatic Pancreatic Cancer Gemcitabine has been standard of care for over a decade various trials adding other cytotoxics have shown a (marginal) survival benefit with increased toxicity* Two recent trials however showed clear superiority of novel regimens: FOLFIRINOX in the French PRODIGE 4 / ACCORD 11 Gem/ nab-paclitaxel in MPACT Trial *Ciliberto D et al. Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials. Eur J Cancer 2013; 49:
21 Gemcitabine Established as Treatment Standard for PDAC over 20 Years Ago First-line gemcitabine vs 5- FU in advanced pancreatic cancer Median OS: 5.7 vs 4.4 mos (P =.0025); 1-yr OS: 18% vs 2% Clinical benefit (pain + KPS + weight): 23.8% vs 4.8% (P =.0022) OS (%) Gemcitabine 5-FU Mos Burris HA, et al. J Clin Oncol. 1997;15:
22 FOLFIRINOX Trial Trial Schema Patient Characteristics
23 FOLFIRINOX Trial - Toxicity
24 OS 11.1 vs. 6.8 months HR 0.55, p< No PD at FOLFIRINOX Gem 6 months 52.8% 17.2% 12 months 12.1% 3.5% 18 months 3.3% 0 %
25 Time until definitive deterioration of QoL FOLFIRINOX Gemcitabine
26 MPACT Trial Median OS 8.5 vs. 6.7 months Median PFS 5.5 vs. 3.7 months Survival Response Rate 23% vs. 7%
27 Sequential nab-pacli followed by gem 24 hours later might be superior PDAC mouse model suggested that nabp potentiates GEM activity by reducing cytidine deaminase levels and scheduling may be important 146 patients randomized to concurrent vs. sequential nabp and Gem Sequential Concomitant 6 m PFS 47% 33% Median PFS months HR 0.66, CI Median OS 10.1 months 7.9 months HR.88, CI More side effects (hematological, fatigue, QoL deterioration) in SEQ group Philippa Corrie, Abs 4100 ASCO 2017
28 Comparative Effectiveness of nab-paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Nationwide Chart Review in the United States Sunnie Kim et al, ASCO GI Cancers Symposium 2018
29 Comparative Effectiveness of nab-paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Nationwide Chart Review in the United States Sunnie Kim et al, ASCO GI Cancers Symposium 2018
30 Comparative Effectiveness of nab-paclitaxel Plus Gemcitabine vs FOLFIRINOX in Metastatic Pancreatic Cancer: A Nationwide Chart Review in the United States Sunnie Kim et al, ASCO GI Cancers Symposium 2018
31 UpToDate 2018
32 Second Line Therapy
33 Meta-analysis on 2 nd line Therapy for PDAC 5 Studies with 895 patients receiving monofluoropyrimidine(fp) chemo or combinations of FP and Irinotecan or Oxaliplatin HR FP+Iri vs. FP 0.64 ( , p=0.005) for PFS and 0.7 ( , p=0.004) for OS HR FP+Ox modest improvement for PFS and none for OS Sunbol et al, Cancer, 2017; 123:
34 Second Line Therapy after Gemcitabine based Therapy CONKO-003 Study: 168 patients age 18 years or older who experienced disease progression during first-line gemcitabine therapy were randomly assigned to folinic acid and fluorouracil (FF) or oxaliplatin and FF (OFF) Median OS in the OFF group (5.9 months) versus the FF group (3.3 months) significantly improved (HR 0.66; 95% CI, 0.48 to 0.91; log-rank P =.010). Similar AEs except neuropathy Oettle et al. J Clin Oncol Aug 10;32(23): doi: /JCO
35 Phase III Experience: Second-line Chemotherapy With Oxaliplatin CONKO-003 [1] PANCREOX [2] Pts (N = 268) PD on Gem(n = 160) Previous Gem (n = 108) Treatment OFF 5-FU/LV mfolfox6 5-FU/LV (n = 76) (n = 84) (n = 54) (n = 54) OS, median 5.9 mos 3.3 mos 6.1 mos 9.9 mos HR: 0.66 (95% CI: ) P =.01 HR: 1.78 (95% CI: ) P =.02 PFS, median 2.9 mos 2.0 mos 3.1 mos 2.9 mos HR: 0.68 (95% CI: ) P =.02 HR: 1.00 (95% CI: ) P =.99 ORR, median NR 13.2% 8.5% P = Oettle H, et al. J Clin Oncol. 2014;32: Gill S, et al. J Clin Oncol Sep 12.
36 NAPOLI-1: Nanoliposomal Irinotecan With 5-FU/LV After Previous Gemcitabine-Based Treatment Study design: Phase 3, open-label RCT; mpdac progress on Gem-based treatment Randomization: nal-iri (MM-398) (n = 151) 5-FU + LV (n = 119) or nal-iri + 5-FU + LV (n = 117) Primary endpoint: OS Secondary endpoints: PFS, TTF, ORR, and safety Nanoliposomal irinotecan: Enhanced tumor penetration and retention - EPR. Wang-Gillam A et al;. Lancet. 2016;387:
37 What after FOLFIRINOX? Second-Line Therapy in the ACCORD / Prodige Trial FOLFIRINOX group: n= 80 patients Gemcitabine group n= 85 patients mos both groups: 4.4 months in each group 2 nd line: after FOLFIRINOX gemcitabine: 82.5% gemcitabine-based combination: 12.5% After gemcitabine: FOLFOX: 49.4% Gemcitabine plus oxaliplatin: 17.6% 5-FU/LV plus cisplatin: 16.5% FOLFIRINOX: 4.7% Conroy et al., 2011
38 Cave: Not randomized cohort trial N = 57 Median 4 cycles Gem + nab-pac 17.5% ORR mpfs: 5.1 mo mos: 8.8 (18) mo G 3/4 AEs: 40% Neutropenia 12.5% Neurotoxicity 12.5% Asthenia 9% Thrombopenia 6.5% OS and PFS PFS: 5.1 mo OS and PFS since first-line chemotherapy Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after FOLFIRINOX failure: an AGEO prospective multicentre cohort. Portal A et al, Br J Cancer Sep;113(7):989-95
39 Optimal therapeutic sequence? First-line FOLFIRINOX Gem Gem + Nab-P Second-line Gemcitabine Gem + Nab-P? Nal-IRI + 5-FU FOLFIRI Ox + FP? FOLFIRINOX? Nal-IRI + 5-FU? FOLFIRI? Ox + FP? FOLFIRINOX? Quality of life is paramount in this setting we need data!
40 Novel Approaches to PDAC Systemic Treatment
41 Hyaluronan: Major Component of the Extracellular Matrix PEGPH20: recombinant human hyaluronidase Hyaluronan degradation can Normalize tumor interstitial pressure Improve drug delivery
42 Phase II HALO : Addition of PEGPH20 to Gem/Nab-Pac in Metastatic Pancreatic Cancer Pts with stage IV pancreatic cancer, no prior treatment for metastatic disease, KPS 70% (planned N = 279) Gemcitabine 1000 mg/m 2 + Nab-Paclitaxel 125 mg/m 2 1 x/wk for 3/4 wks/cycle PEGPH20 3 µg/kg IV 2x/wk in cycle 1 then weekly + Gemcitabine 1000 mg/m 2 + Nab-Paclitaxel 125 mg/m 2 1 x/wk for 3/4 wks/cycle Treat until progression, intolerable toxicity, death, or choice to discontinue Primary endpoint: PFS Secondary endpoints: ORR, OS, safety, PK
43 Phase II HALO : Preliminary Results Outcome by Population Gem + Nab-P + PEGPH20 Gem + Nab-P P Value HR Total Median PFS, mos ORR, % (n/n) (30/74) (21/61) HA-high Median PFS, mos ORR, % (n/n) (12/23) (5/21) HA-low Median PFS, mos ORR, % (n/n) (14/38) (9/24) Higher rate of thromboembolic events on PEGPH20-containing arm during first stage of enrollment (42% vs 25%); mitigated during second stage with addition of prophylactic enoxaparin [1] Phase III HALO study of gem/nab-p PEGPH20 limited to HA-high pts currently enrolling [2]
44 Immune Checkpoint Inhibitors in PDAC Minimal to no activity in advanced PDAC 1% of pancreatic cancers associated with defective mismatch repair (dmmr/msi-high) I 2 of 4 dmmr/msi-high pts on pembrolizumab had objective responses Change From Baseline SLD (%) Target Lesion Measurements P P P Gastric Ampullary Small bowel Pancreatic Cholangio P
45 BRCA- or PALB2-mutation carriers Objective responses in early trials: Rucaparib: 3/19 (16%) Olaparib: 5/23 pts (22%) Veliparib: 0/16 pts
46 Molecular classification and transcriptional networks 32 mutated genes 10 signaling pathways Kras, TGFb, WNT, Notch, ROBO/SLIT, G1/S transition, SW1-SNF, chromatin modification, DNA repair, RNA processing 4 subtypes Squamous Mutations in P53 and KDM6A (lysin demethylase), p63dn Worst prognosis ADEK (aberrantly differentiated endocrine exocrine) Kras activation Endocrine (NEUROD1, NKX2-2) und exocrine (NR5A2, RBPJL) differentiation Pancreatic progenitor FOX2/3, PDX1, MNX1 Immunogenic P Bailey et al. Nature 1-6 (2016)
47 Conclusions Improving frontline and second-line treatment options 2 frontline regimens, FOLFIRINOX and gemcitabine/nab-paclitaxel, have demonstrated survival benefit (vs gemcitabine alone) in phase III studies Evidence for second-line/salvage treatment in this disease with (nanoliposomal) irinotecan plus 5-FU/LV following gemcitabine-based therapy Novel therapeutics under investigation may one day complement, but are unlikely to replace, standard cytotoxic agents Include stromal-depleting agents, immunotherapies, and signal transduction inhibitors New approaches to molecularly subclassify pancreatic cancer may one day allow us to make smarter treatment decisions
48 Non-metastatic Pancreatic Cancer
49 Pancreatic Cancer Resection Categories Resectable Borderline resectable A distinct category Neoadjuvant therapy may increase likelihood of R0 resection Unresectable (eg, locally advanced or metastatic) Ryan, David et al, New England Journal of Medicine. 371(11): , 2014 Cancer of the pancreas: ESMO Clinical Practice Guidelines, Ducreux M et al,
50 Resectability in Pancreatic Adenocarcinoma Pancreatic Adenocarcinoma. Ryan, David; Hong, Theodore; Bardeesy, Nabeel New England Journal of Medicine. 371(11): , DOI: /NEJMra
51 Management of localized resectable disease Upfront surgery (Whipple procedure) recommended neoadjuvant chemotherapy may lead to fewer resections due to PD - newer regimens may be more effective but as yet untested
52 en bloc removal of: Distal stomach Duodenum Head of pancreas Distal bile duct Gallbladder Proximal jejunum Whipple Procedure (Pancreatoduodenectomy)
53 Adjuvant Therapy for Pancreatic Cancer Adjuvant chemotherapy is standard Role of adjuvant RT is debated, even in R1 resected patients Old trials showed benefit of chemotherapy vs. observation (ESPAC 1) and Gemcitabine vs. Bolus 5-FU Integration of more active regimens is attractive and off label use is increasing, no clinical trial evidence
54 ESPAC 1 Bolus 5FU/FA vs. No Chemotherapy MS 20.1 vs months (p = 0.009) 2 y OS 40% vs. 30% BOLUS 5FU/ FA N Engl J Med Mar 18;350(12):
55 CONKO-001 (2007 data) Gemcitabine vs. No Chemotherapy R vs 7.3 months R vs 5.5 months JAMA. 2007;297:
56 CONKO-001 (2013 update) Gemcitabine vs. No Chemotherapy Median DFS 13.4 months vs. 6.7 months (HR 0.55) OS Benefit from Gemcitabine (HR 0.76, p = 0.01) 5 y Survival 20.7 vs % 10 y Survival 12.2 vs. 7.7 % JAMA. 2013;310(14):
57 Cunningham D et al. JCO 27: 5513, 2009 Neoptolemos J et al. ASCO 2016
58 ASCO 2016
59 53 resectable PDAC trials on clinicaltrials.gov
60 Upfront Resectable Pancreatic Cancer Primary Surgery versus Neoadjuvant Chemo Database of 15,237 patients, stage I or II resected pancreatic head Adenocarcinoma 2,005 patients (95%) receiving Neoadjuvant Chemo matched with 6,015 patients with primary surgery Chemo first group had improved survival compared with Surgery first group: median survival: 26 months versus 21 month, P < 0.01; HR 0.72 Surgery first patients vs. Chemo first patients: higher pathologic T stage (pt3 and T4: 86% v 73%; P <.01) higher positive lymph nodes (73% v 48%; P <.01) higher positive resection margin (24% v 17%; P <.01) Mokdad AA et al. J Clin Oncol 2016, Sept
61 Many ongoing trials looking at best strategy ESPAC-5F: randomised patients to 4 approaches
62 Borderline Resectable Disease Potential benefits of primary chemotherapy Better diffusion of chemotherapy in wellvascularized tissues (before surgery and radiotherapy) Better tolerance and feasibility in patients before surgery (50% of adjuvant postoperative treatment not done or uncompleted) Decrease of the delay to the first treatment Downstaging effect Exclusion of patients with rapidly progressive tumours
63 Recent meta-analysis of primary chemotherapy with FOLFIRINOX 13 studies with FOLFIRINOX 689 patients 355 Locally advanced 63.5% received RT-CT after FOLFIRINOX Suker M et al. Lancet Oncol 2016;17:801-10
64 Localised Primarily Unresectable Disease Much controversy Primary chemotherapy standard Possibly followed by radiochemotherapy * (LAP07 trial was negative but a retrospective analysis of pts in the National Cancer Database showed that patients receiving (SB)RT did better than those only on chemo ASCO 2017, Abs 4103) Radiological reassessment is poor in identifying patients who are likely resectable -If some response documented resubmit to MDT discussion and consider exploratory surgery
65 Current Chemotherapy Sequencing for Metastatic PDAC First Line Gemcitabine based (eg, gem/nab-paclitaxel) Poor PS: Gemcitabine FOLFIRINOX; fluoropyrimidinebased therapy + oxaliplatin Second Line (PS 0/1): Nanoliposomal irinotecan + 5-FU; fluoropyrimidine-based therapy PS 2: Fluoropyrimidine alone or BSC PS 0/1: Gemcitabine-based (eg, gem/nab-paclitaxel, gemcitabine) PS 2 or less: Gemcitabine monotherapy or BSC Third line PS 0/1: Platinum (??)-based regimen if no prior exposure or BSC??
Pancreatic Ductal Adenocarcinoma. Razvan Popescu Tumor Center Aarau Switzerland
Pancreatic Ductal Adenocarcinoma Razvan Popescu Tumor Center Aarau Switzerland Median Survival of Patients With Pancreatic Cancer Localized/ Resectable 15-24 months 10% Locally Advanced 6-15 months 30%
More informationPancreatic Ca Update
Pancreatic Ca Update Caio Max S. Rocha Lima, M.D. M. Robert Cooper Professor in Medical Oncology Co-leader GI Oncology and Co-leader Phase I Program Wake Forest School of Medicine E-mail:crochali@wakehealth.edu
More informationPancreatic Adenocarcinoma
Pancreatic Adenocarcinoma AProf Lara Lipton 28 April 2018 Percentage alive 5 years after diagnosis for men and women Epidemiology 6% of cancer related deaths worldwide 4 th highest cause of cancer death
More informationCase 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First?
Case 1 Metastatic Pancreatic Adenocarcinoma: What Therapy Should I Select First? Marc Peeters, MD, PhD Head of the Oncology Department Antwerp University Hospital Antwerp, Belgium marc.peeters@uza.be 71-year-old
More informationOverview. What s New in the Treatment of Pancreatic Cancer? Lots! Steven J. Cohen, M.D. Fox Chase Cancer Center September 17, 2013
What s New in the Treatment of Pancreatic Cancer? Lots! Steven J. Cohen, M.D. Fox Chase Cancer Center September 17, 2013 Overview Staging and Workup Resectable Disease Surgery Adjuvant therapy Locally
More informationAdjuvant therapy in pancreatic cancer Monotherapy for whom? JL VAN LAETHEM, MD,PhD
Adjuvant therapy in pancreatic cancer Monotherapy for whom? JL VAN LAETHEM, MD,PhD Efficacy Parameters in adjuvant monochemotherapy Randomized studies in resectable PDAC Regimen DFS HR (p) OS HR (p) 5-yr-OS
More informationWhat Is The Optimal Adjuvant Therapy in Pancreatic Adenoca: Intensified Chemotherapy March 28 th, 2015
What Is The Optimal Adjuvant Therapy in Pancreatic Adenoca: Intensified Chemotherapy March 28 th, 2015 Eileen M. O Reilly, M.D. Associate Director David M. Rubenstein Center Pancreatic Cancer Research
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More informationASCO Poster Review PANCREATIC CANCER
ASCO Poster Review PANCREATIC CANCER Dr.ssa Michela Squadroni U.O. Oncologia Humanitas Gavazzeni Bergamo TOPICAL ISSUES Gemcitabine/Nab-paclitaxel and FOLFIRINOX comparison Neoadjuvant and perioperative
More informationReference No: Author(s) 12/05/16. Approval date: committee. June Operational Date: Review:
Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) Guidelines for Pancreatic Adenocarcinoma Dr Colin Purcell, Consultant Medical Oncologist & on behalf of the GI Oncologists Group, Cancer
More informationLA CHEMIOTERAPIA DI I LINEA
DECIDERE LA CHEMIOTERAPIA ADIUVANTE E DELLA MALATTIA METASTATICA LA CHEMIOTERAPIA DI I LINEA Michele Reni Department of Medical Oncology IRCCS Ospedale San Raffaele Milan, Italy 1930 1940 1950 1960 1970
More informationIntended for use by Clinicians and Health Care Providers involved in the Management or Referral of adult patients with pancreatic
Intended for use by Clinicians and Health Care Providers involved in the Management or Referral of adult patients with pancreatic cancer Section AA Cancer Centre Referrals In the absence of metastatic
More informationPancreatic Cancer. Maribel Tirado Gomez, MD Hematology and Medical Oncology
Pancreatic Cancer Maribel Tirado Gomez, MD Hematology and Medical Oncology Disclosures I have no actual or potential financial or commercial conflict of interest in relation to this presentation. Consulting
More informationUpdate on Pancreatic Cancer
Update on Pancreatic Cancer Farshid Dayyani, MD, PhD Associate Clinical Professor, Department of Medicine, UC Irvine School of Medicine February 2 nd, 2018 Overview Current Systemic Treatments Adjuvant
More informationGI Tumor Board 3/8/2018. Case #1 IDEA. Case #1 Question #1 What is the next step in management?
GI Tumor Board Edward Kim George Poultsides Naseem Esteghamat Kenzo Hirose May Cho Alan Venook Arta Monjazeb Margaret Tempero George Fisher Andrew Ko Daniel Chang Thomas Semrad Sisi Haraldsdottir Case
More informationChemotherapy for Advanced Gastric Cancer
Chemotherapy for Advanced Gastric Cancer Andrés Cervantes Professor of Medicine DISCLOSURE OF INTEREST Employment: None Consultant or Advisory Role: Merck Serono, Roche, Beigene, Bayer, Servier, Lilly,
More informationPancreatic Cancer: Medical Therapeutic Approaches
Pancreatic Cancer: Medical Therapeutic Approaches Vincent J Picozzi MD MMM Virginia Mason Medical Center Seattle WA 1 Pancreatic cancer is the hardest cancer of all to treat Pancreatic cancer: Why so difficult
More informationDr Roopinder Gillmore July 2017
Dr Roopinder Gillmore July 2017 Resectable Borderline / locally advanced Metastatic 15-20% 15-20% 60-70% 22-28 months 9-15 months 6-12 months Does the patient have resectable disease?? Definitely not
More informationPancreatic Cancer: Light at the End of the (Very Long) Tunnel
Pancreatic Cancer: Light at the End of the (Very Long) Tunnel Daniel Renouf, MD, MPH, FRCPC Medical Oncologist, BC Cancer Agency University of British Columbia Objectives 1. Discuss recent updates in systemic
More informationFuture Perspectives in mpca. Michel Ducreux, MD, PhD Gustave Roussy Villejuif, France
Future Perspectives in mpca Michel Ducreux, MD, PhD Gustave Roussy Villejuif, France Number of Novel Therapies and Targets in Pancreatic Cancer Are Expanding Garrido-Laguna I, et al. Nat Rev Clin Oncol.
More informationPancreatic Cancer. BIOLOGY: Not well defined (genetic and enviromental factors) CLINICAL PRESENTATION: Abd pain, jaundice, weight loss.
EloreMed Editor: Le Wang, MD, PhD Date of Update: 2/6/2018 UpToDate: Liposomal irinotecan (Onivyde) plus FU/LV is now approved for gemcitabine-refractory metastatic pancreatic cancer and recommended by
More informationCáncer de Páncreas: Optimización del tratamiento sistémico
Cáncer de Páncreas: Optimización del tratamiento sistémico Alfredo Carrato Hospital Universitario Ramón y Cajal, Madrid 16 de Mayo de 2015 Pancreatic cancer screening There is a latency period of about
More informationPancreatic Cancer and Radiation Therapy
Pancreatic Cancer and Radiation Therapy Why? Is there a role for local therapy with radiation in a disease with such a high rate of distant metastases? When? Resectable Disease Is there a role for post-op
More informationPancreatic Cancer Where are we?
Pancreatic Cancer Treatment Approaches & Options Pancreatic Cancer Action Network OUMC 9/22/2016 Russell G. Postier, MD Pancreatic Cancer Where are we? Estimated 2016 data 3% of cancer cases 7% of cancer
More informationBest Practices and Promising Agents in Pancreatic Cancer. This program is supported by educational grants from Celgene Corporation and Incyte.
Best Practices and Promising Agents in Pancreatic Cancer This program is supported by educational grants from Celgene Corporation and Incyte. About These Slides Users are encouraged to use these slides
More informationPancreas Cancer Update Systemic Treatments
Pancreas Cancer Update Systemic Treatments Carlos R Becerra. Baylor University Medical Center Stage Distribution for Pancreas Cancer in the US (24-21) 1 9 8 7 Axis Title 6 5 4 53 3 28 2 1 9 11 Localized
More informationConcept to Practice: New Advances in the Treatment of GI Cancers
Concept to Practice: New Advances in the Treatment of GI Cancers 2016 Community Oncology Alliance Conference Orlando, FL Thomas George, MD, FACP Director, GI Oncology Program Director, Experimental Therapeutics
More informationCHEMOTHERAPY FOR METASTATIC GASTRIC CANCER
CHEMOTHERAPY FOR METASTATIC GASTRIC CANCER Dr Elizabeth Smyth Royal Marsden, UK ESMO Gastric Cancer Preceptorship Valencia 2017 IMPORTANT CONSIDERATIONS WHEN TREATING ADVANCED GASTRIC CANCER Short OS Pain
More informationState of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan
State of the Art: Colorectal Cancer Liver Metastasis Dr. Iain Tan Consultant GI Medical Oncologist National Cancer Centre Singapore Clinician Scientist, Genome Institute of Singapore OS (%) Overall survival
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More informationTough to treat tumors in elderly. how far can we go? Jean-Luc Raoul Institut Paoli-Calmettes Marseille France
Tough to treat tumors in elderly Pancreatic cancer: how far can we go? Jean-Luc Raoul Institut Paoli-Calmettes Marseille France Top 5 causes of cancer death / age Cancer Statistics in the USA 2008, CA
More informationAlliance A Alliance SWOG ECOG/ACRIN - NRG
Preoperative chemotherapy and chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas Alliance A021501 Alliance SWOG ECOG/ACRIN - NRG Clinical
More informationTreatment Approaches for Pancreatic Cancer: Hope on the Horizon Disclosures
Treatment Approaches for Pancreatic Cancer: Hope on the Horizon Michael Pishvaian, MD, PhD Director, Phase I Program Assistant Professor Lombardi Comprehensive Cancer Center Georgetown University Disclosures
More informationTogether, putting patients first
The Role of a Gastroenterologist in the Diagnosis and Management of Pancreatic Cancer Sarah Jowett, Consultant Gastroenterologist Bradford Teaching Hospitals Trust Leeds Regional Study Day, 12 September
More informationPancreas Quizzes c. Both A and B a. Directly into the blood stream (not using ducts)
Pancreas Quizzes Quiz 1 1. The pancreas produces hormones. Which type of hormone producing organ is the pancreas? a. Endocrine b. Exocrine c. Both A and B d. Neither A or B 2. Endocrine indicates hormones
More informationAdjuvant Chemotherapy for Rectal Cancer: Are we making progress?
Adjuvant Chemotherapy for Rectal Cancer: Are we making progress? Hagen Kennecke, MD, MHA, FRCPC Division Of Medical Oncology British Columbia Cancer Agency October 25, 2008 Objectives Review milestones
More informationReference No: Author(s) Approval date: 12/05/16. Committee. June Operational Date: Review:
Reference No: Title: Author(s) Systemic Anti-Cancer Therapy (SACT) Guidelines for Biliary Tract Cancer (BTC) Dr Colin Purcell, Consultant Medical Oncologist on behalf of the GI Oncologists Group, Cancer
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationMEETING SUMMARY ESMO 2018, Munich, Germany. Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER
MEETING SUMMARY ESMO 2018, Munich, Germany Dr. Jenny Seligmann University of Leeds, UK HIGHLIGHTS ON COLORECTAL CANCER DISCLAIMER Please note: The views expressed within this presentation are the personal
More informationChemotherapy of colon cancers
Chemotherapy of colon cancers Stage distribution Stage I : 15% T 1,2 NO Stage IV: 20 25% M+ Stage II : 20 30% T3,4 NO Stage III N+: 30 40% clinical stages I, II, or III colon cancer are at risk for having
More informationVan Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
Efficacy Results from the ToGA Trial: A Phase III Study of Trastuzumab Added to Standard Chemotherapy in First-Line HER2- Positive Advanced Gastric Cancer Van Cutsem E et al. Proc ASCO 2009;Abstract LBA4509.
More informationPRIMARY THROMBOPROPHYLAXIS IN AMBULATORY CANCER PATIENTS: CURRENT GUIDELINES
PRIMARY THROMBOPROPHYLAXIS IN AMBULATORY CANCER PATIENTS: CURRENT GUIDELINES Mario Mandalà, MD Unit of Clinical Research Department of Oncology and Haematology Papa Giovanni XXIII Hospital Cancer Center
More informationEpidemiology, aetiology and the patient pathway in oesophageal and pancreatic cancers
Epidemiology, aetiology and the patient pathway in oesophageal and pancreatic cancers Dr Ian Chau Consultant Medical Oncologist Women's cancers Breast cancer introduction 3 What profession are you in?
More informationFoROMe Lausanne 6 février Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV
FoROMe Lausanne 6 février 2014 Anita Wolfer MD-PhD Cheffe de clinique Département d Oncologie, CHUV Epithelial Ovarian Cancer (EOC) Epidemiology Fifth most common cancer in women and forth most common
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationQuimioteràpia per l'adenocarcinoma de pàncrees. Com són de bons els resultats? Que esperem en un futur pròxim?
Quimioteràpia per l'adenocarcinoma de pàncrees. Com són de bons els resultats? Que esperem en un futur pròxim? Carles Pericay (Oncologia. Hospital Parc Taulí) Projecting Cancer Deaths to 2030 Lung Rahib
More informationY A L E S C H O O L O F M E D I C I N E. This is a CME accredited activity. The presenters and there are no conflicts of interest.
This is a CME accredited activity. The presenters and there are no conflicts of interest. Pain in Pancreatic Cancer More than 50% of patients with pancreatic cancer suffer from abdominal and back pain
More informationImmunotherapy in head and neck cancer and MSI in solid tumors
Immunotherapy in head and neck cancer and MSI in solid tumors Brian Hunis, MD, MBA Associate Medical Director, Memorial Cancer Institute. Hollywood, FL »No disclosures Objectives»Discuss the role of immunology
More informationImmunotherapy for Breast Cancer. Aurelio B. Castrellon Medical Oncology Memorial Healthcare System
Immunotherapy for Breast Cancer Aurelio B. Castrellon Medical Oncology Memorial Healthcare System Conflicts Research support : Cascadian therapeutics, Puma biotechnology, Odonate therapeutics, Pfizer,
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationColon Cancer Update Christie J. Hilton, DO
POMA Winter Conference Christie Hilton DO Medical Oncology January 2018 None Colon Cancer Numbers Screening (brief update) Practice changing updates in colon cancer MSI Testing Immunotherapy in Colon Cancer
More informationSurgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14
Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related
More informationAdvances in Chemotherapy of Colorectal Cancer
Advances in Chemotherapy of Colorectal Cancer Richard M. Goldberg Lineberger Comprehensive Cancer Center University of North Carolina at Chapel Hill Disease Settings Adjuvant Therapy MOSAIC, FOLFOX Andre
More informationS u p p o r t e d b y a n i n d e p e n d e n t E d u c a t i o n a l G r a n t f r o m B a y e r
EXPERTS KNOWLEDGE SHARE with Prof. Köhne, Dr. Modest and Dr. Vecchione Madrid (Spain) Sunday September 10 th 2017 S u p p o r t e d b y a n i n d e p e n d e n t E d u c a t i o n a l G r a n t f r o m
More informationThe 2010 Gastrointestinal Cancers Symposium Oral Abstract Session: Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract
The 2010 Gastrointestinal Cancers Symposium : Cancers of the Pancreas, Small Bowel and Hepatobilliary Tract Abstract #131: Phase I study of MK 0646 (dalotuzumab), a humanized monoclonal antibody against
More informationAdvances in gastric cancer: How to approach localised disease?
Advances in gastric cancer: How to approach localised disease? Andrés Cervantes Professor of Medicine Classical approach to localised gastric cancer Surgical resection Pathology assessment and estimation
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationSystemic management of pancreatic cancer: Supportive care
Systemic management of pancreatic cancer: Supportive care Snežana Bošnjak Institute for Oncology and Radiology of Serbia Dept. Supportive Oncology & Palliative Care Serbia, Belgrade Integrative Oncology
More informationJonathan Dickinson, LCL Xeloda
Xeloda A blockbuster in the making Jonathan Dickinson, LCL Xeloda Xeloda unique tumor-activated mechanism Delivering more cancer-killing agent straight into cancer Highly effective comparable efficacy
More informationΚίκα Πλοιαρχοπούλου. Παθολόγος Ογκολόγος Ευρωκλινική Αθηνών
Κίκα Πλοιαρχοπούλου Παθολόγος Ογκολόγος Ευρωκλινική Αθηνών Time (months) Survival outcomes in mcrc have progressively improved over the past two decades Treatment options for many patients Multidisciplinary
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Nab-Paclitaxel (Abraxane) for Pancreatic Cancer September 23, 2014
pan-canadian Oncology Drug Review Final Clinical Guidance Report Nab-Paclitaxel (Abraxane) for Pancreatic Cancer September 23, 2014 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More informationDevelopment of a Clinical and research program in Pancreatic Cancer. The Problem
Development of a Clinical and research program in Pancreatic Cancer Malcolm Moore BC Cancer Agency The Problem By 2020 Pancreatic Cancer (PDAC) will be the second leading cause of cancer death. 5-year
More informationADJUVANT CHEMOTHERAPY FOR RECTAL CANCER
ESMO Preceptorship Programme Colorectal Cancer Barcelona November, 25-26, 2016 ADJUVANT CHEMOTHERAPY FOR RECTAL CANCER Andrés Cervantes Professor of Medicine OLD APPROACH TO RECTAL CANCER Surgical resection
More informationASCO 2017 updates in Colorectal and Gastric Cancers. May Cho, M.D.
ASCO 2017 updates in Colorectal and Gastric Cancers May Cho, M.D. Relevant financial relationships in the past twelve months by presenter or spouse/partner: None The speaker will directly disclosure the
More informationDALLA CAPECITABINA AL TAS 102
DALLA CAPECITABINA AL TAS 102 Milano 29 settembre 2016 LE PROSPETTIVE NELLA RICERCA Armando Santoro Humanitas Cancer Center THE 1,2.AND 3 LINE CHEMOTHERAPY IN CRC M BEVACIZUMAB AFLIBERCET RAS wt RAS mu
More informationL oncologo Alberto Zaniboni
COME TRATTARE LA NEOPLASIA LOCALMENTE AVANZATA BORDERLINE PER RESECABILITA L oncologo Alberto Zaniboni Oncologia Medica Fondazione Poliambulanza - Brescia Pancreatic cancer deaths in 2030 Pancreatic cancer
More informationAdjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009
HIGHLIGHT ARTICLE - Slide Show Adjuvant Treatment of Pancreatic Cancer in 2009: Where Are We? Highlights from the 45 th ASCO Annual Meeting. Orlando, FL, USA. May 29 - June 2, 2009 Muhammad Wasif Saif
More informationAdjuvant/neoadjuvant systemic treatment of colorectal cancer
5th ESO-ESMO Eastern Europe and Balkan Region Masterclass in Medical Oncology Belgrade, June 19 th 2018 Adjuvant/neoadjuvant systemic treatment of colorectal cancer Carlotta Antoniotti Polo Oncologico
More informationWhere are we with radiotherapy for biliary tract cancers?
Where are we with radiotherapy for biliary tract cancers? Professor Maria A. Hawkins Associate Professor in Clinical Oncology MRC Group Leader/Honorary Consultant Clinical Oncologist CRUK MRC Oxford Institute
More informationPromoting Innovative Practice
Promoting Innovative Practice Development of centralised care in advanced pancreatic cancer 1 Dr Olosula O Faluyi, Consultant in Medical Oncology and Dr Daniel H Palmer, Chair in Medical Oncology, Clatterbridge
More informationTowards an optimal treatment algorithm for metastatic pancreatic ductal adenocarcinoma (PDA)
REVIEW ARTICLE Towards an optimal treatment algorithm for metastatic pancreatic ductal adenocarcinoma (PDA) M. Uccello md,* M. Moschetta PhD md,* G. Mak md,* T. Alam BSc (Hons),* C. Murias Henriquez md,*
More informationClinical trials updates: current and future cholangiocarcinoma trials
U C L C A N C E R I N S T I T U T E Clinical trials updates: current and future cholangiocarcinoma trials John Bridgewater UCL Cancer Institute AMMF Information Day Imperial College, 10 May 2016 U C L
More informationThird Line and Beyond: Management of Refractory Colorectal Cancer
Third Line and Beyond: Management of Refractory Colorectal Cancer George A. Fisher MD PhD Stanford University 1 Overview Defining the chemo refractory and intolerant Agents approved in 3 rd line setting
More informationTumors in the Randomized German AIO study KRK-0306
FOLFIRI plus Cetuximab versus FOLFIRI plus Bevacizumab as First- Line Treatment for Patients with Metastatic Colorectal Cancer (mcrc): Analysis of Patients with KRAS-Mutated Tumors in the Randomized German
More informationThis page explains some of the medical words that you may hear when you are finding out about pancreatic cancer and how it is treated.
A-Z of medical words This page explains some of the medical words that you may hear when you are finding out about pancreatic cancer and how it is treated. Absorption: once your food has been broken down,
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationUpdated Apr 2017 by Dr. Ko (Medical Oncologist, Abbotsford Cancer Centre)
Metastatic Esophagogastric Cancer Summary Updated Apr 2017 by Dr. Ko (Medical Oncologist, Abbotsford Cancer Centre) Reviewed by Dr. Yoo-Joung Ko (Medical Oncologist, Sunnybrook Odette Cancer Centre, University
More informationADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS. Andrés Cervantes. Professor of Medicine
ADVANCED COLORECTAL CANCER: UNRESECTABLE OR BORDERLINE RESECTABLE (GROUP 1) CHEMOTHERAPY +/- TARGETED AGENTS Andrés Cervantes Professor of Medicine 1995 One option Advances in the treatment of mcrc 2000
More informationAre we making progress? Marked reduction in operative morbidity and mortality
Are we making progress? Surgical Progress Marked reduction in operative morbidity and mortality Introduction of Minimal-Access approaches for complex esophageal cancer resections Significantly better functional
More informationGeneral Information, efficacy and safety data
Horizon Scanning in Oncology Horizon Scanning in Oncology 23 rd Prioritization 2 nd quarter 2015 General Information, efficacy and safety data Eleen Rothschedl Anna Nachtnebel Priorisierung XXIII HSS Onkologie
More informationTristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease
Tristate Lung Meeting 2014 Pro-Con Debate: Surgery has no role in the management of certain subsets of N2 disease Jennifer E. Tseng, MD UFHealth Cancer Center-Orlando Health Sep 12, 2014 Background Approximately
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationCONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS
CONSIDERATIONS IN DEVELOPMENT OF PEMBROLIZUMAB IN MSI-H CANCERS December 2017 Christine K. Gause, Ph.D Executive Director, Biostatistics. 2 Microsatellite Instability-High Cancer - USPI KEYTRUDA is indicated
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationCetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer
Cetuximab with Chemotherapy as Treatment for Stage III Colon or Metastatic Colorectal Cancer Cetuximab with Chemotherapy (CT) as First-Line Treatment for Metastatic Colorectal Cancer (mcrc): Analysis of
More informationPancreatic cancer from the past to the future
Pancreatic cancer from the past to the future Darren Sigal, MD Scripps Clinic Pancreas and Bile Duct Cancer Group Division of Hematology/Oncology Scripps Clinic Pancreas and Bile Duct Cancer Group 1 Objectives
More informationSurgical Management of Pancreatic Cancer
I Congresso de Oncologia D Or July 5-6, 2013 Surgical Management of Pancreatic Cancer Michael A. Choti, MD, MBA, FACS Department of Surgery Johns Hopkins University School of Medicine, Baltimore, MD Estimated
More informationTHE ROLE OF RADIATION THERAPY IN MANAGEMENT OF PANCREATIC ADENOCARCINOMA. TIMUR MITIN, MD, PhD
THE ROLE OF RADIATION THERAPY IN MANAGEMENT OF PANCREATIC ADENOCARCINOMA TIMUR MITIN, MD, PhD RESECTABLE DISEASE MANAGEMENT: RESECTABLE DISEASE Resection offers the only possibility of long term survival
More informationAdjuvant therapies for large bowel cancer Wasantha Rathnayake, MD
LEADING ARTICLE Adjuvant therapies for large bowel cancer Wasantha Rathnayake, MD Consultant Clinical Oncologist, National Cancer Institute, Maharagama, Sri Lanka. Key words: Large bowel; Cancer; Adjuvant
More informationpan-canadian Oncology Drug Review Final Economic Guidance Report Irinotecan liposome (Onivyde) for Metastatic Pancreatic Cancer January 5, 2018
pan-canadian Oncology Drug Review Final Economic Guidance Report Irinotecan liposome (Onivyde) for Metastatic Pancreatic Cancer January 5, 2018 DISCLAIMER Not a Substitute for Professional Advice This
More informationCholangiocarcinoma. GI Practice Guideline. Michael Sanatani, MD, FRCPC (Medical Oncologist) Barbara Fisher, MD, FRCPC (Radiation Oncologist)
Cholangiocarcinoma GI Practice Guideline Michael Sanatani, MD, FRCPC (Medical Oncologist) Barbara Fisher, MD, FRCPC (Radiation Oncologist) Approval Date: October 2006 This guideline is a statement of consensus
More informationGI ONCOLOGY CLINICAL TRIALS AT UCDAVIS
G ONCOLOGY CLNCAL TRALS AT UCDAVS Version: DECEMBER 2017 Please contact us with any questions or any potential clinical patients Edward Kim, MD/PhD email: jhkim@ucdavis.edu pager: 916-816-4059 May Cho,
More informationDR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID
DR LUIS MANSO UNIDAD TUMORES DE MAMA Y GINECOLÓGICOS HOSPITAL 12 DE OCTUBRE MADRID RESUMEN DE ARTICULOS THERESA BOLERO 3 NOAH UP-DATE GEPAR SIXTO RADIOTHERAPY EBCTCG CTCs MISCELANEAS Lancet Oncol 2014;
More informationNeo- and adjuvant treatment for gastric cancer: The role of chemotherapy
Anna Dorothea Wagner, PD & MER Department of Oncology University of Lausanne Neo- and adjuvant treatment for gastric cancer: The role of chemotherapy Structure 1. Background and overview 2. Adjuvant chemotherapy:
More informationWeitere Kombinationspartner der Immunotherapie
1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationSBRT in Pancreas Cancer Role of The Radiosurgery Society
SBRT in Pancreas Cancer Role of The Radiosurgery Society Anand Mahadevan MD FRCS FRCR Chairman Division of Radiation Oncology Geisinger Health System, Danville, PA, USA. Past President and Chairman: The
More informationPancreas Case Scenario #1
Pancreas Case Scenario #1 An 85 year old white female presented to her primary care physician with increasing abdominal pain. On 8/19 she had a CT scan of the abdomen and pelvis. This showed a 4.6 cm mass
More informationADJUVANT CHEMOTHERAPY...
Colorectal Pathway Board: Non-Surgical Oncology Guidelines October 2015 Organization» Table of Contents ADJUVANT CHEMOTHERAPY... 2 DUKES C/ TNM STAGE 3... 2 DUKES B/ TNM STAGE 2... 3 LOCALLY ADVANCED
More information